Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy

Overview

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in osteoporosis patients:

1. The administration period of teriparatide is less than 6 months and thereafter, denosumab for 24 months.
2. The administration period of teriparatide is from 6 to 12 months and thereafter, denosumab for 24 months.
3. The administration period of teriparatide is more than 12 months and thereafter, denosumab for 24 months.

Eligibility

Inclusion Criteria:

• Osteoporotic patients who want to take teriparatide and denosumab

Exclusion Criteria:

• Patients who are allergic to teriparatide or denosumab Patients who are pregnant or breast-feedin